<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754063</url>
  </required_header>
  <id_info>
    <org_study_id>38RC14.039</org_study_id>
    <nct_id>NCT02754063</nct_id>
  </id_info>
  <brief_title>Impact of Early Optimization of Brain Oxygenation on Neurological Outcome After Severe Traumatic Brain Injury</brief_title>
  <acronym>OXY-TC</acronym>
  <official_title>Impact of Early Optimization of Brain Oxygenation on Neurological Outcome After Severe Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-traumatic brain hypoxia/ischemia develops hours after traumatic brain injury (TBI), and
      its intensity is directly related to the neurological outcome. The thresholds for
      irreversible tissue damage following TBI indicate a particular vulnerability of injured
      brain. Improving brain oxygenation after severe TBI is the focus of modern TBI management in
      the intensive care unit (ICU).

      The calculation of cerebral perfusion pressure (CPP), with CPP = mean arterial pressure (MAP)
      - intracranial pressure (ICP), has become the most used estimator of cerebral blow flow. To
      prevent ischemia due to elevated ICP, current international guidelines recommend maintaining
      CPP at 60-70 mmHg and ICP below 20 mmHg. However, episodes of brain hypoxia/ischemia, as
      assessed with brain tissue oxygen pressure (PbtO2) measurements, might occur despite
      optimization of CPP and ICP, and have been independently associated with poorer patient
      outcome. PbtO2 values lower than 15 mmHg for more than 30 minutes were shown to be an
      independent predictor of unfavorable outcome and death. The aggressive treatment of low PbtO2
      was associated with improved outcome compared to standard ICP/CPP-directed therapy in cohort
      studies of severely head-injured patients. On the basis of these findings, it is hypothesized
      that an early optimization of brain oxygenation, together with keeping ICP and CPP within
      recommended values, could reduce the volume of vulnerable lesions following severe TBI and
      possibly improve neurological outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological outcome according to the extended Glasgow Outcome Scale (GOSE) blind assessed</measure>
    <time_frame>at 6 months post-trauma</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological outcome according to the extended Glasgow Outcome Scale (GOSE) and Disability Rating Scale</measure>
    <time_frame>at 12 months post-trauma (GOSE)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability Rating Scale (DRS)</measure>
    <time_frame>at 6 and 12 months post-trauma</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment: Functional Independence Measure (FIM) and Medical Outcomes Study Short-Form 12 (SF-12)</measure>
    <time_frame>at 6 and 12 months post-trauma</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>at day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic intensity as reflected by the number of level 2 and level 3 treatments to treat elevated ICP</measure>
    <time_frame>during the first 5 days of the ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of critical events as defined by: ICP &gt;30 mmHg during 30 min at least ICP &gt;40 mmHg during 5 min at least PbtO2 &lt;10 mmHg during 30 min at least (PbtO2 group)</measure>
    <time_frame>during the first 5 days of the ICU stay</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Ancillary outcome : Volume of cerebral lesions with abnormal MD values, i.e., decreased or increased MD values, using diffusion tensor MR imaging</measure>
    <time_frame>at day 6-10 following initiation of cerebral monitoring after severe TBI</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <arm_group>
    <arm_group_label>ICP Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PbtO2 + ICP Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PbtO2 probes</intervention_name>
    <description>PbtO2/ICP/CPP-directed therapy according to international recommendations</description>
    <arm_group_label>PbtO2 + ICP Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No PbtO2 probes</intervention_name>
    <description>ICP/CPP-directed therapy according to international recommendations</description>
    <arm_group_label>ICP Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 75

          -  Severe non- penetrating TBI (GCS score 3-8) with motor Glasgow score between 1 and 5

          -  Possible associated extracranial lesions, except tetraplegia

          -  Initiation of cerebral monitoring within the first 16 hours since primary
             traumaticinjury

          -  Indication of ICP monitoring on admission as part of the management

          -  Indication of continuous sedation/analgesia for more than 48 hours

          -  Under mechanical ventilation with stable conditions: PaO2//FiO2 over 150 and PaCO2
             between 35 and 45 mmHg, mean arterial pressure over 70 mmHg

          -  Written informed consent from legal surrogate, patient's relative or investigator
             decision

          -  Affiliation to the French Social Security or affiliated to a social security system of
             EU member state, Norway, Lichtenstein, Iceland or Switzerland

          -  French-speaking or English-speaking patient

        Exclusion Criteria:

          -  Penetrating TBI

          -  GCS 3 with bilateral fixed dilated pupils

          -  Decompressive craniectomy and no repositioning of the bone flap after subdural
             hematoma evacuation surgery prior to enrolment

          -  Contraindication of ICP and/or PbtO2 monitoring, i.e., hemostasis disorders and brain
             tissue infection

          -  Persistent hemodynamic or respiratory instability despite treatments, i.e., mean
             arterial pressure &lt; 70 mmHg, PaO2/FiO2 &lt;150, PaCO2 &lt;30 mmHg or &gt;45 mmHg or lactate &gt;5
             mmol/l if available.

          -  Hypothermia &lt;34°C at randomization

          -  Life expectancy &lt; 24 hours

          -  Cardiac arrest at initial presentation

          -  Tetraplegia

          -  Neuropsychiatric co-morbidities that could interfere with 6 and 12-months assessment
             outcomes.

          -  Consent refusal

          -  Pregnancy

          -  Participation in another therapeutic study with written consent

          -  Inability to have a 6-months follow-up

          -  Ischemic stroke after carotid arterial dissection

          -  Incapacitated patients in accordance with article L 1121-5 to L1121-8 of the public
             health code.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François PAYEN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion RICHARD</last_name>
    <phone>0033476766729</phone>
    <email>MRichard7@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital of Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel GAY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien PILI-FLOURY, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent COTTENCEAU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell CHABANNE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdelaouid NADJI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre BOUZAT, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Kremlin-Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard VIGUE, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel VEGA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric DAILLER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Marseille-Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle HAMMAD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Marseille-Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas BRUDER, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric GRECO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard AUDIBERT, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole ICHAI, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nimes</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélien DAURAT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Paris-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lamine ABDENNOUR, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire DAHYOT-FIZELIER, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoann LAUNEY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène BRAU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Sud Réunion</name>
      <address>
        <city>Saint Pierre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David COURET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of St-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia BURNOL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien POTTECHER, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ambroise MONTCRIOL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas GEERAERTS, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Cunningham AS, Salvador R, Coles JP, Chatfield DA, Bradley PG, Johnston AJ, Steiner LA, Fryer TD, Aigbirhio FI, Smielewski P, Williams GB, Carpenter TA, Gillard JH, Pickard JD, Menon DK. Physiological thresholds for irreversible tissue damage in contusional regions following traumatic brain injury. Brain. 2005 Aug;128(Pt 8):1931-42. Epub 2005 May 11.</citation>
    <PMID>15888537</PMID>
  </reference>
  <reference>
    <citation>Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care, AANS/CNS, Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons SD, Ullman JS, Videtta W, Wilberger JE, Wright DW. Guidelines for the management of severe traumatic brain injury. IX. Cerebral perfusion thresholds. J Neurotrauma. 2007;24 Suppl 1:S59-64. Erratum in: J Neurotrauma. 2008 Mar;25(3):276-8. multiple author names added.</citation>
    <PMID>17511547</PMID>
  </reference>
  <reference>
    <citation>Oddo M, Levine JM, Mackenzie L, Frangos S, Feihl F, Kasner SE, Katsnelson M, Pukenas B, Macmurtrie E, Maloney-Wilensky E, Kofke WA, LeRoux PD. Brain hypoxia is associated with short-term outcome after severe traumatic brain injury independently of intracranial hypertension and low cerebral perfusion pressure. Neurosurgery. 2011 Nov;69(5):1037-45; discussion 1045. doi: 10.1227/NEU.0b013e3182287ca7.</citation>
    <PMID>21673608</PMID>
  </reference>
  <reference>
    <citation>van den Brink WA, van Santbrink H, Steyerberg EW, Avezaat CJ, Suazo JA, Hogesteeger C, Jansen WJ, Kloos LM, Vermeulen J, Maas AI. Brain oxygen tension in severe head injury. Neurosurgery. 2000 Apr;46(4):868-76; discussion 876-8.</citation>
    <PMID>10764260</PMID>
  </reference>
  <reference>
    <citation>Stiefel MF, Spiotta A, Gracias VH, Garuffe AM, Guillamondegui O, Maloney-Wilensky E, Bloom S, Grady MS, LeRoux PD. Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitoring. J Neurosurg. 2005 Nov;103(5):805-11.</citation>
    <PMID>16304983</PMID>
  </reference>
  <reference>
    <citation>Narotam PK, Morrison JF, Nathoo N. Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy. J Neurosurg. 2009 Oct;111(4):672-82. doi: 10.3171/2009.4.JNS081150.</citation>
    <PMID>19463048</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

